Evidence map›Paper›PMID 26301593›Full record

ArticlePloS one2015

Source and Purity of Dengue-Viral Preparations Impact Requirement for Enhancing Antibody to Induce Elevated IL-1β Secretion: A Primary Human Monocyte Model.

Justin B Callaway, Scott A Smith, Douglas G Widman, Karen P McKinnon, Frank Scholle, Gregory D Sempowski, Dirk P Dittmer, James E Crowe, Aravinda M de Silva, Jenny P-Y Ting

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Justin B CallawayDepartment of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America; The Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.
Scott A SmithThe Vanderbilt Vaccine Center, Vanderbilt Medical Center, Nashville, TN, United States of America; Department of Medicine, Vanderbilt Medical Center, Nashville, TN, United States of America.
Douglas G WidmanDepartment of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.
Karen P McKinnonDepartment of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America; The Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.
Frank ScholleDepartment of Biological Sciences, North Carolina State University, Raleigh, NC, United States of America.
Gregory D SempowskiDuke Human Vaccine Institute, Durham, NC, United States of America.
Dirk P DittmerDepartment of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America; The Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.
James E CroweThe Vanderbilt Vaccine Center, Vanderbilt Medical Center, Nashville, TN, United States of America; Department of Pathology, Microbiology and Immunology, Vanderbilt Medical Center, Nashville, TN, United States of America; Department of Pediatrics, Vanderbilt Medical Center, Nashville, TN, United States of America.
Aravinda M de SilvaDepartment of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.
Jenny P-Y TingDepartment of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America; The Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America; Department of Genetics, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.
University of North Carolina at Chapel Hill · USVanderbilt University Medical Center · USNorth Carolina State University · US

Funding

Yessinia autotransporters (Yaps): Structure, function, and host responseU54AI057157 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SEMPOWSKI, GREGORY D · 2003 to 2013
$91.4M
Tissue Procurement & PathologyP50CA058223 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa A. Troester · 1992 to 2026
$59.3M
Protein Expression/Dengue Virology CoreU19AI109784 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TING, JENNY P · 2014 to 2018
$20.8M
Regional Biocontainment Laboratory (RBL)UC6AI058607 · NIAID · DUKE UNIVERSITY · PI WILLIAMS, R SANDERS · 2003 to 2005
$16.3M
Proteomics Pathway DiscoveryU19AI109965 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DUNCAN, JOSEPH A · 2014 to 2018
$14.9M
Study of Novel HHV8/KSHV Encoded GenesU19AI107810 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DITTMER, DIRK P · 2013 to 2017
$10.6M
ART Modulation of Viral Pathogenesis in Oral EpitheliaR01DE018304 · NIDCR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DITTMER, DIRK P · 2007 to 2025
$6.9M
BASIC IMMUNE MECHANISMST32AI007273 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TISCH, ROLAND M · 1985 to 2020
$5.6M
Key determinants of dengue virus neutralization by naturally occurring human mAbsK08AI103038 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SMITH, SCOTT ALAN · 2012 to 2016
$631k
Role of NLRX1 in dengue virus infectionF32AI094941 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WIDMAN, DOUGLAS G · 2011 to 2012
$74k
NCI NIH HHS 2P50CA058223-19A1NCI NIH HHS P30CA06086NCI NIH HHS P50 CA058223NIAID NIH HHS 1F32AI094941-01NIAID NIH HHS 5T32AI007273-29NIAID NIH HHS 5U19AI107810-02NIAID NIH HHS F32 AI094941NIAID NIH HHS T32 AI007273NIAID NIH HHS U19 AI107810NIAID NIH HHS U19 AI109784NIAID NIH HHS U19-AI109784NIAID NIH HHS U19 AI109965NIAID NIH HHS U19-AI109965NIAID NIH HHS U54 AI057157NIAID NIH HHS U54-AI057157NIAID NIH HHS UC6 AI058607NIAID NIH HHS UC6AI058607NIDCR NIH HHS R01 DE018304NIDCR NIH HHS R01-DE018304
6 · The paper itself

Abstract

Dengue virus is a major global health threat and can lead to life-threatening hemorrhagic complications due to immune activation and cytokine production. Cross-reactive antibodies to an earlier dengue virus infection are a recognized risk factor for severe disease. These antibodies bind heterologous dengue serotypes and enhance infection into Fc-receptor-bearing cells, a process known as antibody-dependent enhancement of infection. One crucial cytokine seen elevated in severe dengue patients is IL-1β, a potent inflammatory cytokine matured by the inflammasome. We used a highly-physiologic system by studying antibody-dependent enhancement of IL-1β in primary human monocytes with anti-dengue human monoclonal antibodies isolated from patients. Antibody-enhancement increased viral replication in primary human monocytes inoculated with supernatant harvested from Vero cells infected with dengue virus serotype 2 (DENV-2) 16681. Surprisingly, IL-1β secretion induced by infectious supernatant harvested from two independent Vero cell lines was not enhanced by antibody. Secretion of multiple other inflammatory cytokines was also independent of antibody signaling. However, IL-1β secretion did require NLRP3 and caspase-1 activity. Immunodepletion of dengue virions from the infectious supernatant confirmed that virus was not the main IL-1β-inducing agent, suggesting that a supernatant component(s) not associated with the virion induced IL-1β production. We excluded RNA, DNA, contaminating LPS, viral NS1 protein, complement, and cytokines. In contrast, purified Vero-derived DENV-2 16681 exhibited antibody-enhancement of both infection and IL-1β induction. Furthermore, C6/36 mosquito cells did not produce such an inflammatory component, as crude supernatant harvested from insect cells infected with DENV-2 16681 induced antibody-dependent IL-1β secretion. This study indicates that Vero cells infected with DENV-2 16681 may produce inflammatory components during dengue virus propagation that mask the virus-specific immune response. Thus, the choice of host cell and viral purity should be carefully considered, while insect-derived virus represents a system that elicits antibody-dependent cytokine responses to dengue virus with fewer confounding issues.

Indexed as

AnimalsAntibodies, NeutralizingAntibodies, ViralChlorocebus aethiopsDengue VirusHumansInterleukin-1betaMonocytesSevere DengueVero CellsVirus ReplicationAntibodies, NeutralizingAntibodies, ViralInterleukin-1beta

Identifiers

PMID26301593
PMCPMC4547738
OpenAlexW1870527452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.